50 years ago: Chinese herb medicine cures cancer

1. At a Glance

• This is an archival item from The Hindu's "50 years ago" column. It reports a claim from Tokyo that a Chinese herbal preparation developed by Japanese scientists was "remarkably effective" against cancer [1].
• The preparation had about 30 herbs and was based on recipes in an ancient Chinese medical text. It was reported to cause fewer adverse effects than standard anti-cancer drugs [1].
• Why it matters for UPSC: it is a historical case study for current debates on Traditional, Complementary and Integrative Medicine (TCIM), on evidence standards (a small sample with no controls), and on WHO's Global Traditional Medicine Strategy 2025–2034, in which India plays a leading role [2][6].

2. Why in the News

• The item was reprinted in The Hindu's Chennai print edition on 26 October 2026, page 9, as a 50-year look-back [1].
• Current context:
• The Global Traditional Medicine Strategy 2025–2034 was adopted at the 78th World Health Assembly (WHA78), May 2025 [2].
• The 2nd WHO Traditional Medicine Summit was held in New Delhi [7].
• The WHO Global Traditional Medicine Centre (GTMC) published its Annual Report 2025 [4].

3. Background & Evolution

• Original report (dateline Tokyo, October 25; 1976, going by the 50-year column): scientists at Osaka University and the Oriental Medicine Research Institute of "Kink University" (spelling as printed) developed the preparation [1].
• Before human use: the formula was finalised after three years of animal tests [1].
• Clinical phase: experiments ran from 1974 on advanced cancer cases at hospitals attached to the two universities [1].
• Reported outcome:
• 9 of 13 patients "made good progress" [1].

• One patient resumed normal life even though rectal cancer had recurred and spread [1].

• Cancers that improved: breast, abdominal, rectal and uterine [1].

• Classical claim: the source text said the recipe worked for breast and skin cancer [1].
• Later global milestones:
• 2022: WHO GTMC launched with Government of India support. PM Narendra Modi inaugurated it with WHO Director-General Dr Tedros Adhanom Ghebreyesus [6].
• 2023: the World Health Assembly asked WHO to draft a new strategy for 2025–2034 [2].
• 21 March 2024: WHO set out an evidence-based roadmap for GTMC collaborations [5].
• May 2025: WHA78 adopted the strategy [2].

4. Core Static Facts

Item	Fact
Nature of the 1970s preparation	Multi-herb formulation, ~30 herbal medicines [1]
Knowledge base	Recipes in an ancient Chinese medicine book [1]
Institutions	Osaka University; Oriental Medicine Research Institute of "Kink University" [1]
Pre-clinical work	3-year animal testing [1]
Clinical start	1974, advanced cancer cases [1]
Sample / response	13 patients, 9 improved [1]
Claimed advantage	Comparatively few adverse effects [1]
WHO strategy	Global Traditional Medicine Strategy 2025–2034, adopted at WHA78 (May 2025) [2]
Strategy's 4 objectives	(i) strengthen evidence; (ii) ensure safety and regulation; (iii) integrate TCIM into health systems; (iv) optimise cross-sectoral value [2]
WHO GTMC	Global knowledge hub on traditional medicine. Launched 2022 with India's support [3][6]
GTMC focus areas	Data collection, analytics, impact assessment [4]
India's stance	Supports the strategy; stresses evidence-based integration of traditional medicine into national health systems [6]

5. Multi-Dimensional Analysis

Scientific / Technological

• The trial had 13 patients, no control arm and no randomisation. "Good progress" was a subjective endpoint. By modern standards this is anecdotal evidence, not efficacy [1].
• A formula with ~30 herbs makes it hard to tell which active compound is doing the work, to standardise doses, and to reproduce batches [1].
• WHO's first strategic objective is "strengthen evidence", which is exactly the gap in claims like this one [2].

Ethical / Governance

• A headline saying an herb "cures cancer" is a misinformation risk. Patients may delay proven treatment.
• The strategy's objective on safety and regulation addresses quality control, adulteration and misleading claims [2].
• It raises questions of informed consent and research ethics when experimental remedies are given to advanced-stage patients [1].

Geopolitical / Strategic

• India presents traditional medicine (Ayush) as health diplomacy. Examples: hosting the WHO GTMC (2022) and the 2nd WHO TM Summit in New Delhi [6][7].
• Japan, China and India each turn their own traditional systems into soft power and industry. The 1970s Japan–China herbal link is an early example [1].

Economic

• Herbal formulations feed a large phytopharmaceutical and nutraceutical value chain. Raw material comes from medicinal-plant cultivation and wild collection.
• The strategy's objective on cross-sectoral value covers economic, biodiversity and cultural gains [2].

Historical

• The item shows that the effort to validate classical texts with laboratory and clinical methods (here, animal tests followed by hospital cases) is at least 50 years old [1].

Environmental

• Formulas that use many herbs raise demand for wild medicinal plants. This links TCIM to biodiversity conservation and access and benefit-sharing (ABS). The strategy also counts biodiversity among its cross-sectoral concerns [2].

6. Recent Developments (last 12–18 months)

• February 2025 (EB156): India made a statement to the WHO Executive Board on the draft traditional medicine strategy [6].
• May 2025 (WHA78): the Global Traditional Medicine Strategy 2025–2034 was adopted, and India's statement supported it [2][6].
• 2025: the WHO GTMC Annual Report 2025 came out, highlighting data, analytics and impact assessment [4].
• 14 November 2025: WHO reported growing leadership engagement for evidence-based traditional medicine ahead of the 2nd WHO Traditional Medicine Summit, New Delhi [7].
• 26 October 2026: The Hindu reprinted the 1976 cancer-herb item [1].

7. Prelims Hooks

• The 1970s preparation had about 30 herbal medicines [1].
• It was developed at Osaka University with a university Oriental Medicine Research Institute in Japan, not in China, although it was based on Chinese texts [1].
• Its basis was recipes in an ancient Chinese medical book, described as effective for breast and skin cancer [1].
• Three years of animal testing came before human use [1].
• Clinical experiments began in 1974 on advanced cancer cases [1].
• 9 of 13 treated patients showed good progress [1].
• The Global Traditional Medicine Strategy covers 2025–2034 [2].
• The strategy was adopted at the 78th World Health Assembly, May 2025 [2].
• The WHA asked for the strategy in 2023 [2].
• The strategy has four objectives: evidence; safety and regulation; integration of TCIM into health systems; cross-sectoral value [2].
• TCIM stands for Traditional, Complementary and Integrative Medicine [2].
• The WHO Global Traditional Medicine Centre was launched in 2022 with Government of India support [6].
• GTMC inauguration: PM Narendra Modi with WHO DG Dr Tedros [6].
• The 2nd WHO Traditional Medicine Summit was held in New Delhi [7].

8. How Artemisinin Succeeded Where This Formula Did Not

• Both started from an old Chinese text. Only one became a medicine.
• In 1969 Tu Youyou led Project 523, a Chinese government search for a malaria cure [11].
• She found a mention of qinghao (sweet wormwood, Artemisia annua) for malaria fevers in Ge Hong's A Handbook of Prescriptions for Emergencies, written around 317–420 AD [11].

• Her team took one plant, pulled out one compound (artemisinin) and tested that compound alone. She won the Nobel Prize in Physiology or Medicine in 2015 [11].

• Why the 30-herb route usually stops early

• With one compound, scientists can fix the dose, check its purity and repeat the trial anywhere.
• With about 30 herbs in a mix [1], no one knows which herb is working, or whether some herbs cancel others out. Each batch can also be different.

• So 9 of 13 patients improving [1] gives a lead to follow, not a product to approve.

• What to take away for an answer: a classical text is a good place to start looking for a drug. It is not proof that the drug works. Artemisinin shows the full path: text → one plant → one compound → trials → WHO approval.

9. Why India's Law Against False 'Cure' Claims Is Weak in Practice

• The law exists, but each state has to enforce it
• The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 bans adverts that claim to cure listed diseases. Cancer is one of them [8].
• In December 2018 the Centre added Rule 170 to the Drugs and Cosmetics Rules, 1945. It deals with misleading adverts for Ayurvedic, Siddha and Unani medicines [8].

• Raids and seizures are done by a gazetted officer that the state government authorises under Section 8(1) [8]. The Centre cannot act on its own.

• The body that spots the advert cannot punish anyone

• The Ayush pharmacovigilance programme (a system that tracks harmful side effects of medicines and false claims about them) has three levels: one national centre, 5 intermediary centres and 99 peripheral centres [9].

• When these centres find a misleading advert, they can only send it to the state licensing authority [9]. Whether anything happens next depends on each state.

• The Supreme Court had to fill the gap

• In Writ Petition (Civil) No. 645/2022, the Supreme Court's order of 30 July 2024 asked for one central dashboard to track misleading adverts and adverse drug reactions [10].

• The Ayush Suraksha Portal was launched in May 2025 to follow that order [10]. A court order, not the Ministry, set this up. That shows the earlier system was not working well enough.

• Link to the 1976 headline: "Herb medicine cures cancer" [1] is exactly the kind of claim the 1954 Act bans in adverts. Today's question is not whether such a law exists. It is whether anyone acts on it quickly enough.

10. Countries Register Herbal Medicines but Rarely Track the Harm

• More rules on paper than before
• 124 WHO Member States have a registration system for herbal medicines [12].

• Registration checks a product before it goes on sale.

• Very few countries count the harm after sale

• Only 40% of responding Member States have a patient-safety reporting system that includes harm from TCIM [12].

• So in most countries, if a herbal product hurts someone, the case is never recorded.

• Why this matters for the claim of "fewer side effects"

• The 1976 report said the formula had fewer adverse effects than anti-cancer drugs [1]. That was judged on a handful of patients.
• A medicine can look safe only because nobody is collecting reports of harm. If no data is collected, "no harm reported" proves nothing.
• WHO itself says that setting up pharmacovigilance for traditional medicine products is a common problem across countries [12].

11. Is It Unfair to Test Traditional Medicine Like a Modern Drug?

• The strongest argument against strict testing
• Traditional systems often treat the whole person. Two patients with the same disease may get different mixtures.

• A randomised controlled trial (RCT) (patients are split by chance into a group that gets the medicine and a group that does not, then compared) tests one fixed product. Supporters say this design cannot capture how the system really works.

• What this argument gets right

• The RCT does not have to be copied rigidly. The design can be changed, for example by testing the whole treatment package against usual care.

• Artemisinin also shows that old texts can hold real value that modern science would otherwise miss [11].

• Why the argument fails for a claim like "cures cancer"

• A cancer patient who trusts an unproven cure may delay surgery or chemotherapy. For that patient, the cost of a wrong claim is very high.
• The standard of proof should rise with the size of the claim. The bigger the claim, the stronger the evidence needed.

• The countries pushing traditional medicine accept this. WHO's 2025–2034 strategy puts strengthening evidence as its first objective [2], and India's statements at WHO call for evidence-based integration [6].

• Balanced conclusion for Mains: adapt the trial design to fit the system, but do not lower the standard of proof.

12. Who Must Do What Next

• Ministry of Ayush and states: set a deadline to act on flagged adverts
• Today, pharmacovigilance centres find misleading adverts but can only send them to state authorities [9].

• States should have to act within a fixed time. The result should be shown publicly on the Ayush Suraksha dashboard that the Supreme Court asked for [10]. That way a state that does nothing can be seen doing nothing.

• Ayush research councils: follow the artemisinin path for anti-cancer leads

• Use classical formulas only to find candidate plants. Then isolate and test single compounds, as Tu Youyou's team did [11].

• Any claim about cancer should then go through the New Drugs and Clinical Trials Rules route that modern drugs follow.

• WHO GTMC (Jamnagar-supported hub): build a shared system for reporting harm

• The Centre's mandate covers data collection, analytics and impact assessment [4].

• Only 40% of countries record harm from TCIM [12]. The GTMC is well placed to pool adverse-event data across countries, so that claims like "fewer side effects" can finally be checked.

• Media: say how strong the evidence is

• A report on 13 patients should say clearly that it is a small study with no comparison group. The 1976 headline said "cures" [1]. That is the word the 1954 Act treats as objectionable in an advert [8].

13. Anchors for Answers

• Data: 124 WHO Member States have a herbal-medicine registration system, but only 40% of responding states have patient-safety reporting that covers TCIM [12]
• Data: The Ayush pharmacovigilance network has 1 national, 5 intermediary and 99 peripheral centres [9]
• Report/Committee: WHO Global Report on Traditional, Complementary and Integrative Medicine, 2024 [12]
• Law/Case: Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Section 8(1), enforced by states; Rule 170, Drugs and Cosmetics Rules (inserted 2018) [8]; Supreme Court, WP(C) 645/2022, order of 30 July 2024, which led to the Ayush Suraksha Portal (2025) [10]
• Comparison: China's artemisinin. One herb from a 4th-century text was narrowed to one tested compound. Nobel Prize 2015 [11]
• Scheme: Pharmacovigilance Programme for ASU&H drugs under the Central Sector Scheme AOGUSY (Ayush Oushadhi Gunvatta evam Uttpadan Samvardhan Yojana) [9]

14. Mains Relevance

• GS-II: Health; issues relating to development and management of social sector services; important international institutions (WHO).
• GS-III: Science & Technology, including developments and their applications; indigenous technology; IPR in traditional knowledge.
• GS-IV: Ethics in medical research; integrity in public communication of science.
• Likely question stems: 1. Integrating traditional medicine into public health systems needs rigorous evidence and regulation. Examine with reference to WHO's Global Traditional Medicine Strategy 2025–2034. (GS-II, 250 words) 2. India's hosting of the WHO Global Traditional Medicine Centre is both a health-policy and a soft-power initiative. Discuss. (GS-II) 3. Unverified claims of 'cures' in traditional medicine raise ethical concerns for researchers and the media. Critically analyse. (GS-IV / GS-III)

15. Related Topics to Study Next

• WHO Global Traditional Medicine Centre: India-hosted WHO hub at the centre of the TCIM agenda.
• Ministry of Ayush and the National Ayush Mission: India's institutional framework for traditional systems.
• Traditional Knowledge Digital Library (TKDL): protects Indian traditional knowledge against biopiracy and wrongful patents.
• Biological Diversity Act and ABS / Nagoya Protocol: sourcing medicinal plants and benefit-sharing.
• Drug-discovery examples from traditional medicine, such as artemisinin: the standard example of a classical text leading to a validated drug.
• Drugs and Magic Remedies (Objectionable Advertisements) Act: regulates misleading claims of cures.
• National Cancer Control Programme / NPCDCS (now NP-NCD): India's mainstream cancer-control framework.
• Clinical trial regulation (New Drugs and Clinical Trials Rules): the evidence standards modern claims must meet.

16. NCERT Concepts to Revise

• Traditional knowledge (Economy): The note is about validating classical herbal recipes and India's push to integrate traditional medicine into health systems.
• Access and benefit sharing (Economy): Many-herb formulas need wild medicinal plants, so sourcing them raises consent and benefit-sharing with local communities.
• Nagoya Protocol (Geography): This is the international treaty that governs access to genetic resources and traditional knowledge, linked to herbal sourcing.
• Biopiracy (Economy): Protecting Indian traditional knowledge from wrongful patents, such as through TKDL, is a key related exam theme.
• Misinformation (Polity): A headline saying a herb 'cures cancer' from 13 patients shows how unverified health claims mislead the public.
• Sample (Economy): The trial's weakness was a tiny sample of 13 patients with no control group, so it proves little.

17. Common Errors / Trap Areas

• Country confusion: the research was done in Japan (Osaka) on Chinese classical recipes. Do not call it a Chinese study [1].
• Wrong period: the strategy is 2025–2034, not 2014–2023. That earlier period was the previous strategy cycle. It was adopted at WHA78 (2025), not WHA77 [2].
• Strength of evidence: "9 of 13 improved" in an uncontrolled series does not amount to a proven cure. Watch for "cure" wording in statement-based MCQs [1].
• GTMC details: it is a WHO centre that India supports and hosts, launched 2022. It is not an Ayush Ministry institute [6]. Its location in Jamnagar, Gujarat is widely reported but did not appear in the sources retrieved here, so check it before relying on it.
• Summit numbering: the 2nd WHO TM Summit was in New Delhi [7]. Do not mix it up with the first summit.